Across TCGA pan-cancer cohorts, MIR100 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of MIR100’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where MIR100 RNA is repressed in tumor relative to normal tissue. In most cancer types MIR100 is over-expressed in tumor, although a few such as BRCA show the opposite, repressed pattern.
BRCA are the cancer types where MIR100 tumor–normal differential expression is most reproducible.